MLSS Share Price Performance
US$0.30
-0.63 (-67.82%)
75.9% undervalued intrinsic discount
US$1.25
Fair Value
Price US$0.30
AnalystLowTarget US$1.25
AnalystConsensusTarget US$1.13
AnalystHighTarget US$2.00
Fair ValueUS$1.25
Share Pricen/a
Milestone Scientific Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 1 Fair Values set on narratives written by author
MLSS Community Narratives
AN
Fair Value US$1.25 75.9% undervalued intrinsic discount
Healthcare Cost Pressures Will Limit Adoption Yet Progress Will Emerge
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value US$1.13 73.2% undervalued intrinsic discount
Global Expansion And Minimally Invasive Care Will Shape Future Progress
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value US$2 85.0% undervalued intrinsic discount
Aging Populations And Emerging Markets Will Drive Minimally Invasive Procedures
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Global Expansion And Minimally Invasive Care Will Shape Future Progress
Key Takeaways Medicare reimbursement and rising clinician adoption are expanding the medical segment, driving ongoing revenue growth and broader integration into hospitals and clinics. International sales expansion, operational improvements, and demand for minimally invasive solutions are strengthening margins, recurring revenue, and long-term growth prospects.Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$1.13
73.2% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue
9.19% p.a.
Profit Margin
13.38%
Future PE
71.72x
Price in 2028
US$1.41
Aging Populations And Emerging Markets Will Drive Minimally Invasive Procedures
Key Takeaways Nationwide adoption of medical products, new leadership, and strategic partnerships position the company for rapid, high-margin growth and durable earnings expansion. Global infrastructure, proprietary technology, and competitive moats enable entry into new markets and verticals, sustaining outsized revenue and margin improvements.Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$2
85.0% undervalued intrinsic discount
AnalystHighTarget Fair Value
Revenue
21.74% p.a.
Profit Margin
12.32%
Future PE
98.25x
Price in 2028
US$2.46
Healthcare Cost Pressures Will Limit Adoption Yet Progress Will Emerge
Key Takeaways Premium pricing and cautious healthcare spending could slow adoption and restrict future revenue, especially as hospitals limit capital expenditures. Ongoing net losses and delayed diversification may require new financing, increasing dilution risk and putting pressure on future profit margins.Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$1.25
75.9% undervalued intrinsic discount
AnalystLowTarget Fair Value
Revenue
11.76% p.a.
Profit Margin
12.49%
Future PE
78.48x
Price in 2028
US$1.54
Trending Discussion
Recently Updated Narratives
AN
MLSS: Shares Will Face Key NYSE American Compliance Decision by 2027
Fair Value: US$1.13 73.2% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Healthcare Cost Pressures Will Limit Adoption Yet Progress Will Emerge
Fair Value: US$1.25 75.9% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Aging Populations And Emerging Markets Will Drive Minimally Invasive Procedures
Fair Value: US$2 85.0% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Milestone Scientific Inc. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -0.085
- 71.86%
- -74.66%
- 31.4%
About MLSS
- Founded
- 1989
- Employees
- 17
- CEO
- WebsiteView website
Milestone Scientific Inc., a biomedical technology company, patents, designs, develops, and commercializes diagnostic and therapeutic injection technologies, and devices for medical and dental use in the United States, China, and internationally. It operates through Dental and Medical segments. The company provides the Wand, a single use disposable handpiece device for dental procedures that require local anesthetic under the CompuDent and STA Single Tooth Anesthesia System names. It also offers CompuFlo, a computer-controlled drug delivery system for the painless delivery of drugs, anesthetics, and other medicaments, as well as for the aspiration of bodily fluids or previously injected substances; and disposable injection handpiece for the tactile control during the injection. In addition, the company provides CompuFlo Epidural, a computer-controlled anesthesia system for use in various medical applications. Further, it offers CompuMed for use in various medical procedures performed in plastic, hair restoration, and colorectal surgery, as well as podiatry, dermatology, orthopedics, and various other disciplines. Milestone Scientific Inc. was incorporated in 1989 and is headquartered in Roseland, New Jersey.
